Enlivex Therapeutics (ENLV) Stock Forecast, Price Target & Predictions
ENLV Stock Forecast
Enlivex Therapeutics stock forecast is as follows: an average price target of $15.00 (represents a 893.38% upside from ENLV’s last price of $1.51) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ENLV Price Target
The average price target for Enlivex Therapeutics (ENLV) is $15.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 893.38% upside from ENLV's last price of $1.51.
ENLV Analyst Ratings
According to 2 Wall Street analysts, Enlivex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ENLV stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Enlivex Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 02, 2022 | - | H.C. Wainwright | $15.00 | $5.69 | 163.62% | 893.38% |
The latest Enlivex Therapeutics stock forecast, released on May 02, 2022 by H.C. Wainwright company, set a price target of $15.00, which represents a 163.62% increase from the stock price at the time of the forecast ($5.69), and a 893.38% increase from ENLV last price ($1.51).
Enlivex Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.51 | $1.51 | $1.51 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Enlivex Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enlivex Therapeutics's last price of $1.51. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | EF Hutton | - | Buy | Initialise |
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Enlivex Therapeutics's last stock rating was published by EF Hutton on Aug 27, 2024. The company Initialise its ENLV rating from "null" to "Buy".
Enlivex Therapeutics Financial Forecast
Enlivex Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | 1 | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ENLV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Enlivex Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict ENLV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Enlivex Therapeutics's previous annual EBITDA (undefined) of $NaN.
Enlivex Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - |
| Net Income | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-2.54M | $-2.74M | $-3.13M | $-3.13M | $-3.03M | $-3.62M | $-4.30M | $-4.68M | $-5.21M | $-5.95M |
| High Forecast | $-2.54M | $-2.74M | $-3.13M | $-3.13M | $-3.03M | $-3.62M | $-4.30M | $-4.68M | $-5.21M | $-5.95M |
| Low Forecast | $-2.54M | $-2.74M | $-3.13M | $-3.13M | $-3.03M | $-3.62M | $-4.30M | $-4.68M | $-5.21M | $-5.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ENLV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Enlivex Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Enlivex Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ENLV last annual SG&A of $NaN (undefined).
Enlivex Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.15 | $-0.18 | $-0.22 | $-0.25 | $-0.28 | $-0.32 |
| High Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.15 | $-0.18 | $-0.22 | $-0.25 | $-0.28 | $-0.32 |
| Low Forecast | $-0.13 | $-0.14 | $-0.16 | $-0.16 | $-0.15 | $-0.18 | $-0.22 | $-0.25 | $-0.28 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Enlivex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ENLV previous annual EPS of $NaN (undefined).
Enlivex Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GMDA | Gamida Cell | $0.03 | $7.00 | 23233.33% | Buy |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IPSC | Century Therapeutics | $1.66 | $20.00 | 1104.82% | Buy |
| ENLV | Enlivex Therapeutics | $1.51 | $15.00 | 893.38% | Buy |
| CKPT | Checkpoint Therapeutics | $2.52 | $20.00 | 693.65% | Buy |
| CLGN | CollPlant Bio | $4.85 | $14.00 | 188.66% | Buy |
| KROS | Keros Therapeutics | $55.04 | $105.00 | 90.77% | Buy |
| ALDX | Aldeyra Therapeutics | $5.78 | $10.00 | 73.01% | Buy |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| PPBT | Purple Biotech | $7.37 | $11.00 | 49.25% | - |
| VCEL | Vericel | $44.32 | $57.33 | 29.35% | Buy |
| CRVS | Corvus Pharmaceuticals | $5.50 | $7.00 | 27.27% | Buy |
ENLV Forecast FAQ
Is Enlivex Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Enlivex Therapeutics (ENLV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ENLV's total ratings.
What is ENLV's price target?
Enlivex Therapeutics (ENLV) average price target is $15 with a range of $15 to $15, implying a 893.38% from its last price of $1.51. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Enlivex Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ENLV stock, the company can go up by 893.38% (from the last price of $1.51 to the average price target of $15), up by 893.38% based on the highest stock price target, and up by 893.38% based on the lowest stock price target.
Can Enlivex Therapeutics stock reach $2?
ENLV's average twelve months analyst stock price target of $15 supports the claim that Enlivex Therapeutics can reach $2 in the near future.
What are Enlivex Therapeutics's analysts' financial forecasts?
Enlivex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-15.627M (high $-15.627M, low $-15.627M), average SG&A $0 (high $0, low $0), and average EPS is $-0.81 (high $-0.81, low $-0.81). ENLV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-11.532M (high $-11.532M, low $-11.532M), average SG&A $0 (high $0, low $0), and average EPS is $-0.59 (high $-0.59, low $-0.59).